Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Fasedienol by VistaGen Therapeutics for Anxiety Disorders: Likelihood of Approval
Fasedienol is under clinical development by VistaGen Therapeutics and currently in Phase III for Anxiety Disorders. According to GlobalData, Phase...